To validate that the action of CAL-101 was on-target, PI3K activity was determined in a panel of BCR-dependent ABC DLBCL lines exposed to a range of CAL-101 concentrations, using AKT phosphorylation at threonine 308 (pAKT-308) and serine 473 (pAKT-473) as readouts. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.